PetCaseFinder

Peer-reviewed veterinary case report

Cyclosporin A treatment effects in dogs with intrinsic atopic

By Fujimura, M. et al.·Published in Polish Journal of Veterinary Sciences·2016·View original on Crossref

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Cyclosporin A Treatment in Intrinsic Canine Atopic Dermatitis (Atopic-like Dermatitis): Open Trial Study

Species:
dog

Plain-English summary

A group of dogs with skin problems caused by atopic-like dermatitis (ALD) were treated with an immunosuppressant called Cyclosporin A. While dogs with another type of atopic dermatitis did not show improvement, the majority of those with ALD experienced significant relief, with 11 out of 14 dogs achieving complete remission. The treatment was effective in reducing the severity of their symptoms, allowing many dogs to feel much better. However, one dog in the study had a long treatment duration of over a year and developed other health issues during that time.

People also search for: dog skin problems treatment · Cyclosporin A for dog dermatitis · atopic dermatitis in dogs symptoms

Abstract

Abstract In this study, dogs were separated into two groups and treated with immunosuppressant (Cyclosporin A: CsA). The first group was the canine atopic dermatitis (CAD) group, which is similar to extrinsic atopic dermatitis (AD) in humans (treated with a CsA dose of 2.5-5.5 mg/kg, n=8), and the second group was the canine atopic-like dermatitis (ALD) group, which is similar to intrinsic AD in humans (treated with a CsA dose of 2.5-6.5 mg/kg, n=14). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (PRE) and after treatment (POST) to assess the effectiveness of CsA for the two groups. In the CAD group, CADESI-4 showed no change (PRE:79±29, POST:77±28) and out of the eight dogs, no dogs showed complete remission, three dogs showed partial remission, and five dogs showed no effect. Whereas in the ALD group, CADESI-4 showed a significant reduction (PRE: 61±42, POST: 32±25, p<0.01) and out of the 14 dogs, 11 dogs showed complete remission, two dogs showed partial remission, and one dog showed no effect. The results indicate that the immunosuppressant showed effectiveness for the dogs diagnosed with ALD. One dog had to be treated for a year and eight months, which was the longest period in the study, this dog presented with hyperplasia of the lymphoidgland and mammary tumor.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on Crossref: https://doi.org/10.1515/pjvs-2016-0071